CompletedEarly Phase 1

Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit

United States94 participantsStarted 2017-08-25

Plain-language summary

This multi-center, prospective study will evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with an isolated, closed, posterior wall acetabular fracture managed surgically within 7 days of injury. Upper extremity fractures that are non-operative and have no impact on weight-bearing status will be included.
✓. Patients must be skeletally mature.

Exclusion criteria

✕. Patients are not skeletally mature.
✕. Patients with any concomitant lower extremity, pelvis, or spine injuries.
✕. Patient admitted as a polytrauma patient to the trauma service due to injury to an internal organ (head, chest, or abdomen).
✕. Patient has an unidentified source of hemorrhage other than acetabular fracture.
✕. Patient requires surgery for treatment of concomitant injuries.
✕. Patient requires multiple surgeries.
✕. Patient has pre-existing thrombus prior to surgery.
✕. Patient with a history of prior pulmonary embolus or other thromboembolic disease.

What they're measuring

Hemoglobin (Hb)

Timeframe: Postoperative Day 2

Hematocrit (Hct)

Timeframe: Postoperative Day 2

Trial details

NCT IDNCT05357079

SponsorUniversity of Cincinnati

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-30

View on ClinicalTrials.gov More Fracture of Posterior Wall of Acetabulum trials